What kind of drug is Mirikizumab?

Mirikizumab (Mirikizumab)-Omvoh is a new interleukin-23 antagonist mainly used to treat adults with moderately to severely active ulcerative colitis (UC). The drug is administered intravenously or subcutaneously and specifically targets the p19 subunit of interleukin (IL) 23 to inhibit the IL-23 pathway. IL-23 is a naturally occurring cytokine that plays an important role in normal inflammation and immune responses. However, in patients with ulcerative colitis, overactivation of the IL-23 pathway is thought to be a key contributor to inflammation and related symptoms.

The mechanism of Omvoh is to reduce the intestinal inflammatory response by blocking IL-23 and inhibiting the release of cytokines and chemokines related to inflammation. In October 2023, Omvoh received approval from the U.S. Food and Drug Administration (FDA), marking an important step in its clinical application.

Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulceration of the lining of the large intestine. The pathogenesis of this disease is complex and related to a variety of immune and genetic factors. In particular, the activity of IL-23 is closely related to mucosal inflammation. Clinical studies have shown that in the induction and maintenance phases of treatment for patients with ulcerative colitis, there is a significant positive correlation between the average concentration of Omvoh and clinical remission rate and clinical response, indicating its significant efficacy.

By bindingIL-23 and its receptor, Omvoh effectively inhibits the interaction between these factors and modulates the production of effector cytokines that drive the pathogenesis of ulcerative colitis. This mechanism not only helps improve patients' symptoms, but also provides new ideas and methods for the treatment of chronic inflammatory bowel disease.

Reference materials:https://www.drugs.com/omvoh.html